Jae Yong Cho
Overview
Explore the profile of Jae Yong Cho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
4971
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kang Y, Morita S, Satoh T, Ryu M, Chao Y, Kato K, et al.
Gastric Cancer
. 2021 Sep;
25(1):207-217.
PMID: 34480657
Background: The phase 3 ATTRACTION-2 study demonstrated that nivolumab monotherapy was superior to placebo for patients with pretreated advanced gastric or gastroesophageal junction cancer, but early progression of tumors in...
12.
Kim B, Kim Y, Park I, Cho J, Lee K
World J Clin Cases
. 2021 May;
9(12):2884-2889.
PMID: 33969073
Background: Gastric cancer is the fifth most diagnosed cancer worldwide and the third most common cause of cancer-related death. In recent decades, increasing application of next-generation sequencing has enabled detection...
13.
Boku N, Satoh T, Ryu M, Chao Y, Kato K, Chung H, et al.
Gastric Cancer
. 2021 Mar;
24(4):946-958.
PMID: 33743112
Background: ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with ≥ 2 chemotherapy regimens. However, its long-term efficacy and outcome of...
14.
Park J, Park K, Cho J, Han S, Lee J
Am J Sports Med
. 2021 Mar;
49(5):1220-1226.
PMID: 33661712
Background: Arthroscopic bone marrow stimulation (BMS) is considered the first-line treatment for osteochondral lesions of the talus (OLTs). However, the long-term stability of the clinical success of BMS remains unclear....
15.
Kim J, Han S, Cho J, Chung I, Kim J, Lee K, et al.
Eur J Cancer
. 2020 Mar;
130:51-62.
PMID: 32172198
Background: Cancer-related fatigue (CRF) is a common symptom and has a negative impact on prognosis in cancer patients. CRF could be improved by Korean red ginseng (KRG). Patients And Methods:...
16.
Graphene Foam Cantilever Produced via Simultaneous Foaming and Doping Effect of an Organic Coagulant
Noh S, Park H, Eom W, Lee H, Kang D, Cho J, et al.
ACS Appl Mater Interfaces
. 2020 Jan;
12(9):10763-10771.
PMID: 31985203
Inspired by the role of cellular structures, which give three-dimensional robustness to graphene structures, a new type of graphene cantilever with mechanical resilience is introduced. Here, NHSCN is incorporated into...
17.
Chen L, Satoh T, Ryu M, Chao Y, Kato K, Chung H, et al.
Gastric Cancer
. 2019 Dec;
23(3):510-519.
PMID: 31863227
Background: Nivolumab showed improvement in overall survival (OS) in ATTRACTION-2, the first phase 3 study in patients with gastric/gastroesophageal junction (G/GEJ) cancer treated with ≥ 2 chemotherapy regimens. The 2-year...
18.
Kim D, Lee D, Han J, Lee J, Cho B, Kang J, et al.
Lung Cancer
. 2019 Aug;
135:66-72.
PMID: 31447004
Objectives: The aim of this phase 1/2 study was to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of olmutinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell...
19.
Satoh T, Kang Y, Chao Y, Ryu M, Kato K, Chung H, et al.
Gastric Cancer
. 2019 May;
23(1):143-153.
PMID: 31087200
Background: Data on immune checkpoint inhibitor efficacy in patients with human epidermal growth factor receptor 2-positive (HER2+) advanced gastric/gastroesophageal junction (G/GEJ) cancer are lacking. Because HER2 status was not captured...
20.
Kim T, Han H, Lee K, Zang D, Rha S, Park Y, et al.
Gastric Cancer
. 2019 Apr;
22(6):1206-1214.
PMID: 30945121
Background: Poziotinib (HM781-36B) is an irreversible pan-HER tyrosine kinase inhibitor which targets EGFR, HER2, and HER4. This prospective, multicenter, open-label, phase I/II study determined the maximum tolerated dose (MTD) and...